Login to Your Account



Oncogenex sees bladder cancer benefit in apatorsen

By Michael Fitzhugh
Staff Writer

Wednesday, October 26, 2016

Oncogenex Pharmaceuticals Inc. reported that a combination of its lead anticancer candidate apatorsen and the chemotherapy docetaxel met the primary endpoint of overall survival in the investigator-sponsored phase II Borealis-2 trial.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription